aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
March 06, 2025 16:02 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
March 04, 2025 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
February 24, 2025 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
January 29, 2025 08:00 ET
|
aTyr Pharma, Inc.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
December 12, 2024 16:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
December 10, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
December 09, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
November 15, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
November 07, 2024 16:01 ET
|
aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update